Entrada Therapeutics
TRDA
84 hedge funds and large institutions have $423M invested in Entrada Therapeutics in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 11 reducing their positions, and 9 closing their positions.
282% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
15% more capital invested
Capital invested by funds: $369M → $423M (+$54.3M)
9% more funds holding
Funds holding: 77 → 84 (+7)
2.51% more ownership
Funds ownership: 77.46% → 79.97% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.6M |
| 2 |
Janus Henderson Group
London,
|
+$22M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.42M |
| 4 |
BlackRock
New York
|
+$2.95M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$10.3M |
| 2 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
-$1.29M |
| 3 |
Morgan Stanley
New York
|
-$832K |
| 4 |
Citigroup
New York
|
-$721K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$461K |
TRDA Hedge Fund Activity: Q2 2024 in Review
84 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q2 2024, worth a combined $423M — up 15% from $369M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new TRDA positions and 9 closed out — a net gain of 9 holders — while 42 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.6M. The largest seller was Redmile Group, cutting an estimated $10.3M.
- 84 institutional investors held Entrada Therapeutics (TRDA) as of Q2 2024, up from 77 in Q1 2024.
- Funds reported $423M of Entrada Therapeutics stock for Q2 2024, up 15% quarter-over-quarter.
- 18 funds opened new Entrada Therapeutics positions in Q2 2024 and 9 closed out, a net change of +9 holders.
- The largest Entrada Therapeutics buyer in Q2 2024 was Fidelity Investments, an estimated $23.6M added.
- The largest Entrada Therapeutics seller in Q2 2024 was Redmile Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2024.